Header Image

Latest News

Latest News

Filter Releases
 
Latest News
Date Title and Summary View
Feb 26, 2014
RESEARCH TRIANGLE PARK, N.C., Feb. 26, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results for the fourth quarter and full year ended December 31, 2013. "Since our last quarterly results update, we have initiated the OPuS-1 Phase 2 trial to evaluate orally-administered BCX4161 in patients ...
Feb 25, 2014
RESEARCH TRIANGLE PARK, N.C., Feb. 25, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA...
Feb 20, 2014
RESEARCH TRIANGLE PARK, N.C., Feb. 20, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company's clinical programs at the following investor conferences: The Cowen and Company 34th Annual Health Care Conference...
Feb 12, 2014
RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that its fourth quarter and full year 2013 financial results will be released on Wednesday, February 26, 2014. BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss the financial results and t...
Jan 2, 2014
RESEARCH TRIANGLE PARK, N.C., Jan. 2, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that its executives are scheduled to present a corporate summary and update regarding the Company's development programs at the 32nd annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16th, 2014 at ...
Dec 30, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised an option to conduct the investigational new drug (IND) enabling program and to submit an IND. This option repr...
Dec 20, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New Drug Application (NDA) filing for intravenous...
Dec 18, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that it has selected two optimized plasma kallikrein inhibitors to advance into preclinical development as potential once-daily, oral treatments for the prevention of hereditary angioedema (HAE) a...
Nov 20, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company's clinical programs at the following investor conferences: The 25th Annu...
Nov 7, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that it has dosed the first subject in OPuS-1 (Oral ProphylaxiS-1), a Phase 2a proof of concept clinical trial of orally-administered BCX4161 in patients with hereditary angioedema (HAE). ...
Nov 5, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the third quarter ended September 30, 2013. "Throughout 2013, we have continued to make progress and create value in our core development programs, while we p...
Oct 23, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its third quarter 2013 financial results will be released on Tuesday, November 5, 2013. BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss the financial re...
Sep 17, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID) has contracted with BioCryst for the development of BCX4430 as a treatment for Marburg virus disease. NIAID, part of the Nati...
Sep 3, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company's clinical programs at the Morgan Stanley Global Healthcare Conference in Ne...
Aug 8, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the second quarter ended June 30, 2013. "The fact that we met all of our goals for the BCX4161 Phase 1 trial and secured government funding for the peramivir ...
Page: First Previous
...
...
Next Last